NCIMB, the Aberdeen-based microbiology company, is delighted to welcome Martin Gouldstone as chairman of the board.
Martin brings a wealth of commercial and leadership expertise from drug discovery and contract research. His previous board and advisory roles include non-exec director for hVIVO, an AIM listed viral challenge services business; chair for ValiRx, an AIM listed Biotech company; and advisor to Alden Scientific, post the acquisition of Oncimmune GmbH.
NCIMB is a trusted provider of high-quality microbial products and services that empower innovation, ensure safety, and support sustainable solutions for industries including pharmaceuticals, biotechnology, food & drink, energy, and environmental sectors. The company secured equity investment earlier this year from IFS Mavin Equity Finance and the Scottish National Investment Bank to drive innovative growth in its unique and proprietary microbial strain collection.
Commenting on his appointment Martin said: “NCIMB’s vision is to be the global leader in advancing microbial innovation, fostering sustainable solutions and building a healthier, safer world through trusted science. It’s a fantastic time to be joining the company, which has huge potential for growth through development of its microbial platform to deliver impactful biotechnology solutions addressing grand societal challenges including decarbonisation, food security and healthy living.”
Martin takes over from Barry Phillpott who is stepping down as chairman after a 20-year tenure. Carol Phillips, who joined the board in 2008 and served as CEO for 12 years also stepped down in December.
NCIMB’s CEO Dr Edward Green said: “I would like to take this opportunity to thank Barry and Carol for their immense contribution to the company. They have both been an instrumental part of NCIMB’s success to date. I am looking forward to working with Martin to achieve our vision in this exciting new chapter for the company.”